Targeted therapies in non-muscle-invasive bladder cancer according to the signaling pathways (Q37633006)

21 August 2017

1 reference

title

Targeted therapies in non-muscle-invasive bladder cancer according to the signaling pathways (English)

1 reference

21 August 2017

1 reference

Jean-Christophe Bernhard

object named as

Jean-Christophe Bernhard

2

0 references

Alain Ravaud

object named as

Alain Ravaud

8

0 references

author name string

Hervé Wallerand

1

1 reference

21 August 2017

Stéphane Culine

3

1 reference

21 August 2017

Philippe Ballanger

4

1 reference

21 August 2017

Grégoire Robert

5

1 reference

21 August 2017

Robert E Reiter

6

1 reference

21 August 2017

Jean-Marie Ferrière

7

1 reference

21 August 2017

publication date

13 November 2009

1 reference

21 August 2017

1 reference

21 August 2017

volume

29

1 reference

21 August 2017

issue

1

1 reference

21 August 2017

page(s)

4-11

1 reference

Screening for bladder cancer: a perspective

21 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2009.07.025

Superficial bladder cancer: progression and recurrence

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2009.07.025

Molecular subtypes of bladder cancer: Jekyll and Hyde or chalk and cheese?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2009.07.025

Primary superficial bladder cancer risk groups according to progression, mortality and recurrence.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2009.07.025

Epigenetic gene silencing in cancer – a mechanism for early oncogenic pathway addiction?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2009.07.025

Urothelial tumorigenesis: a tale of divergent pathways

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2009.07.025

Cellular signaling by fibroblast growth factor receptors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2009.07.025

Cell responses to FGFR3 signalling: growth, differentiation and apoptosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2009.07.025

Chromosome 9 deletions are more frequent than FGFR3 mutations in flat urothelial hyperplasias of the bladder.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2009.07.025

Identification of fibroblast growth factor receptor 3 mutations in urine sediment DNA samples complements cytology in bladder tumor detection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2009.07.025

FGFR3 and P53 characterize alternative genetic pathways in the pathogenesis of urothelial cell carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2009.07.025

Frequent activating mutations of FGFR3 in human bladder and cervix carcinomas.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2009.07.025

The phosphotyrosine phosphatase SHP2 is a critical mediator of transformation induced by the oncogenic fibroblast growth factor receptor 3

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2009.07.025

Transformation and Stat activation by derivatives of FGFR1, FGFR3, and FGFR4

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2009.07.025

Prospective study of FGFR3 mutations as a prognostic factor in nonmuscle invasive urothelial bladder carcinomas.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2009.07.025

Molecular profiling of bladder tumors based on the detection of FGFR3 and TP53 mutations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2009.07.025

Accumulation of nuclear p53 and tumor progression in bladder cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2009.07.025

Fibroblast growth factor receptor 1 promotes proliferation and survival via activation of the mitogen-activated protein kinase pathway in bladder cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2009.07.025

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2009.07.025

Role of Ha-ras activation in superficial papillary pathway of urothelial tumor formation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2009.07.025

7 January 2021

Focus on bladder cancer

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2009.07.025

Molecular pathways in invasive bladder cancer: new insights into mechanisms, progression, and target identification

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2009.07.025

FGFR3 and Ras gene mutations are mutually exclusive genetic events in urothelial cell carcinoma.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2009.07.025

The phosphatidylinositol-3 kinase pathway regulates bladder cancer cell invasion

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2009.07.025

The voiding pattern in infants with dilating reflux

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2009.07.025

Uncoupling between epidermal growth factor receptor and downstream signals defines resistance to the antiproliferative effect of Gefitinib in bladder cancer cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2009.07.025

Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2009.07.025

Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2009.07.025

Does HER2/neu expression provide prognostic information in patients with advanced urothelial carcinoma?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2009.07.025

Neovascularisation is a prognostic factor of early recurrence in T1/G2 urothelial bladder tumours

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2009.07.025

Cellular ras activity and tumor cell proliferation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2009.07.025

Growth inhibition of human pancreatic cancer cell lines by anti-sense oligonucleotides specific to mutated K-ras genes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2009.07.025

Farnesyltransferase inhibitors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2009.07.025

Phase I and pharmacokinetic study of the orally administered farnesyl transferase inhibitor R115777 in patients with advanced solid tumors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2009.07.025

Inhibition of human tumor cell growth in vivo by an orally bioavailable inhibitor of human farnesyltransferase, BIM-46228.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2009.07.025

Phase I and pharmacokinetic study of farnesyl protein transferase inhibitor R115777 in advanced cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2009.07.025

Potential roles of antisense technology in cancer chemotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2009.07.025

Biological characterization of ARRY-142886 (AZD6244), a potent, highly selective mitogen-activated protein kinase kinase 1/2 inhibitor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2009.07.025

Activation of MAP kinase kinase is necessary and sufficient for PC12 differentiation and for transformation of NIH 3T3 cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2009.07.025

Integrin αvβ3 Requirement for Sustained Mitogen-activated Protein Kinase Activity during Angiogenesis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2009.07.025

Fibroblast growth factor receptor 3 inhibition by short hairpin RNAs leads to apoptosis in multiple myeloma.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2009.07.025

Oncogenic properties of the mutated forms of fibroblast growth factor receptor 3b.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2009.07.025

Antibody-based targeting of FGFR3 in bladder carcinoma and t(4;14)-positive multiple myeloma in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2009.07.025

Epithelial to mesenchymal transition predicts gefitinib resistance in cell lines of head and neck squamous cell carcinoma and non-small cell lung carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2009.07.025

Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2009.07.025

Lapatinib: a novel dual tyrosine kinase inhibitor with activity in solid tumors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2009.07.025

Efficacy and safety of lapatinib as first-line therapy for ErbB2-amplified locally advanced or metastatic breast cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2009.07.025

Lapatinib moves forward in inflammatory and early HER2-positive breast cancer trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2009.07.025

Sunitinib in patients with metastatic renal cell carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2009.07.025

Dual epidermal growth factor receptor and vascular endothelial growth factor receptor inhibition with vandetanib sensitizes bladder cancer cells to cisplatin in a dose- and sequence-dependent manner.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2009.07.025

BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2009.07.025

10.1016/J.UROLONC.2009.07.025

7 January 2021

Identifiers

DOI

1 reference

21 August 2017

1 reference